ArticleImmunology and cell biology2026
Gamma-irradiated Newcastle disease virus: an alternative inactivated oncolytic virotherapy.
Article in Immunology and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newcastle disease virus (NDV) has been investigated as an oncolytic virus in many clinical trials, demonstrating the ability of NDV to treat a range of different cancers. However, research with NDV is hindered by biosecurity risks associated with live NDV. In addition, NDV is an important poultry pathogen that is associated with widespread livestock losses and a large economic burden. While live and chemically inactivated NDV vaccines are available, they have limited efficacy and there is a need for alternative vaccines. In this study, we inactivated NDV using γ-irradiation and tested the structural integrity, immunogenicity, and oncolytic activity of γ-NDV using in vitro and in vivo models. Our data illustrate that the overall virion structure and protein function of γ-NDV are well maintained. However, we did not detect neutralizing antibody responses after intramuscular or subcutaneous γ-NDV administration in mice. While these data do not directly support the use of γ-NDV as a vaccine candidate, our data show that γ-NDV retained its ability to kill a range of different cancer cells in vitro, suggesting γ-NDV may be a potential cancer therapeutic agent. To test this, γ-NDV was trialed as an oncolytic therapy in a murine melanoma model. This revealed that γ-NDV administration outperformed live NDV in terms of reduced tumor growth and overall survival. While further investigation is required to address the suitability of γ-NDV as a poultry vaccine, our data indicate that γ-irradiation may be a suitable inactivation method for the development of a highly effective inactivated oncolytic virotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.